glp-1 drug news today Swiss Re says drugs could reduce US mortality by up to 6.4% Novo's Wegovy becomes first GLP-1

Description

Pre-clinical and clinical research show a strong connection between fiber intake, microbiome health, and GLP-1 activity

& Camilleri, M

This combination also provides a practical strategy for reducing residual cardiometabolic risk

Less Common but Serious Side Effects Some less common but more serious GLP-1 side effects are worth being aware of: Pancreatitis (inflammation of the pancreas) Gallbladder problems (including gallstones) Acute kidney injury (usually as a result of severe dehydration from vomiting or diarrhea) Diabetic retinopathy worsening (particularly in patients with rapid improvement in blood sugar control) Hypoglycemia (when combined with other diabetes medications like sulfonylureas or insulin) All GLP-1 medications also carry a warning regarding a theoretical risk of medullary thyroid carcinoma, based on animal studies

After a decade of research, Exenatide was approved by the FDA as the worlds first GLP-1 receptor agonist. It forever changed the management of Type 2 diabetes and may prove to be our most powerful weapon in the ongoing war on obesity